全部所有文章

Dr. YwanFeng Li has joined United BioPharma

United BioPharma (UBP, 6471) announced today that Dr. YwanFeng Li has joined our research group in charge of the Quality Control and Medical Affairs Department of United BioPharma. Dr. Li has more than fifteen years experience working in the Center for Drug Evaluation in Taiwan as head of the Division of Pharmaceutical Science. Her specialty is drug discovery, clinical trials and regulatory affairs.

Dr. Lireceived her PhD from the University of North Carolina at Chapel Hill, and then became a postdoc in Fred Hutchinson Cancer Research Center and National Yang-Ming University. She has also served as a technician in the Department of Gynecology and Obstetrics in Taipei Veterans General Hospital, as well as serving as a visiting scholar for Fred Hutchinson Cancer Research and the head of the Center for Drug Evaluation. Dr. Li specializes in chemistry, manufacturing, and control of biopharmaceutical and preclinical studies, such as the pharmacokinetic study. Dr. Mei June Liao, president of United BioPharma, said Dr. Li joining UBP would improve quality control, clinical trials and drug registration of the company. Her involvement in cGMP on-site inspections of our new industrial API facility will accelerate license approval. In addition, her assistance will speed up the progress of having our pipeline products enter into clinical trials.


About United BioPharma (6471)
United BioPharma (UBP) was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnered with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacture, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs to improve the health of mankind. For more information, please visit https://www.ubpglobal.com/

United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.

Contact
Victor Run-Ben Sun
Spokesperson and Vice President of Public Affairs
+886-978-067-006
PR@unitedbiopharma.com
victor.sun@unitedbiopharma.com
回上頁